18-Apr-2024
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
TipRanks (Wed, 17-Apr 5:07 AM ET)
Globe Newswire (Tue, 16-Apr 7:00 AM ET)
NorthStar Appoints Peter Pfreundschuh to Board of Managers
Business Wire (Mon, 15-Apr 9:00 AM ET)
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 26-Mar 4:01 PM ET)
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Globe Newswire (Wed, 13-Mar 7:00 AM ET)
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Globe Newswire (Wed, 28-Feb 4:01 PM ET)
Globe Newswire (Mon, 26-Feb 7:00 AM ET)
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
Globe Newswire (Wed, 21-Feb 7:00 AM ET)
Globe Newswire (Tue, 20-Feb 7:00 AM ET)
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
Globe Newswire (Wed, 7-Feb 7:00 AM ET)
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Voyager Therapeutics trades on the NASDAQ stock market under the symbol VYGR.
As of April 18, 2024, VYGR stock price declined to $7.55 with 986,999 million shares trading.
VYGR has a beta of 1.04, meaning it tends to be more sensitive to market movements. VYGR has a correlation of 0.04 to the broad based SPY ETF.
VYGR has a market cap of $419.71 million. This is considered a Small Cap stock.
Last quarter Voyager Therapeutics reported $90 million in Revenue and $1.25 earnings per share. This beat revenue expectation by $69 million and exceeded earnings estimates by $1.54.
In the last 3 years, VYGR stock traded as high as $14.34 and as low as $2.46.
The top ETF exchange traded funds that VYGR belongs to (by Net Assets): VTI, XBI, VXF, IWM, AVUV.
VYGR has underperformed the market in the last year with a price return of -3.5% while the SPY ETF gained +22.2%. VYGR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.7% and -17.3%, respectively, while the SPY returned +5.2% and -2.6%, respectively.
VYGR support price is $7.39 and resistance is $8.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VYGR stock will trade within this expected range on the day.